TransCelerate BioPharma, a non-profit collaboration of 20 biopharmaceutical firms, is expanding access to Covid-19-linked patient-level clinical data sharing through DataCelerate to non-member companies.
TransCelerate will also expand the kind of data shared to include data from the investigational product and control arms of clinical trials on Covid-19.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This move comes after a decision was taken in May to make use of the DataCelerate platform to share control arm data from clinical studies on Covid-19 that are ongoing and planned.
Claimed to be a global Cloud-based data sharing platform, DataCelerat enables deidentified, anonymised pre-clinical and clinical data types to be requested and shared voluntarily.
Furthermore, the DataCelerate system and accompanying legal agreements offer an internationally compliant system safeguarding privacy rights in clinical data.
Since 2017, TransCelerate members have been using this way to power research activities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDataCelerate is built on AIP+ from Accenture Applied Intelligence and is considered to be fully-secured.
TransCelerate BioPharma CEO Dalvir Gill said: “Time is of the essence to bring together the promising research being done to address this crisis. After our previous announcement, we immediately got to work to provide access, at no cost, for organisations who are developing vaccines and therapeutics for Covid-19.
“We mobilised quickly to overcome technical barriers and ensure patient privacy to rapidly provide a secure way for the biopharmaceutical industry to share patient-level clinical trial data related to the study of this disease. The world is waiting for promising therapies and vaccines to provide relief to the global health and economic crisis. We don’t have the luxury for critical data to be siloed in different organisations.”
In several therapeutic areas, data shared through DataCelerate has already been used to cut down the number of patients in clinical trials, enhance trial design, evaluate safety signals, boost knowledge of disease and treatments, and gain a better understanding of global patient populations.
At least two non-member biopharma companies have expressed an interest in sharing their Covid-19 clinical trial data within DataCelerate, enabling the research community to tap the detailed data as they work on Covid-19 vaccines and treatments.
